Leerink Partnrs Equities Analysts Raise Earnings Estimates for Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc. (NASDAQ:AXNX) – Stock analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Axonics in a research note issued on Thursday, March 28th. Leerink Partnrs analyst M. Kratky now expects that the company will earn $0.36 per share for the year, up from their previous forecast of $0.26. The consensus estimate for Axonics’ current full-year earnings is $0.30 per share. Leerink Partnrs also issued estimates for Axonics’ Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.30 EPS, FY2025 earnings at $0.67 EPS, FY2026 earnings at $1.17 EPS, FY2027 earnings at $1.79 EPS and FY2028 earnings at $2.53 EPS.

Axonics (NASDAQ:AXNX) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.07. The business had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative net margin of 1.66% and a negative return on equity of 1.00%. The firm’s quarterly revenue was up 27.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.01 EPS.

Other analysts have also recently issued reports about the company. Wells Fargo & Company reissued an “equal weight” rating and set a $71.00 price objective (up from $68.00) on shares of Axonics in a report on Wednesday, January 10th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $71.00 price target on shares of Axonics in a research note on Thursday, February 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Wednesday, January 17th. Truist Financial reaffirmed a “hold” rating and issued a $71.00 price target (down from $73.00) on shares of Axonics in a research note on Friday, January 12th. Finally, SVB Leerink reaffirmed a “market perform” rating and issued a $71.00 price target on shares of Axonics in a research note on Friday, January 12th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Axonics has an average rating of “Hold” and a consensus target price of $70.73.

Axonics Price Performance

Shares of NASDAQ:AXNX opened at $68.97 on Friday. Axonics has a 1-year low of $47.59 and a 1-year high of $69.68. The business has a 50-day moving average price of $68.04 and a two-hundred day moving average price of $61.28.

Insider Activity at Axonics

In other Axonics news, insider Karen Noblett sold 15,999 shares of the company’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $69.00, for a total transaction of $1,103,931.00. Following the sale, the insider now directly owns 18,216 shares of the company’s stock, valued at $1,256,904. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Karen Noblett sold 15,999 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $69.00, for a total transaction of $1,103,931.00. Following the completion of the sale, the insider now owns 18,216 shares in the company, valued at approximately $1,256,904. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Kari Leigh Keese sold 3,489 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $236,344.86. Following the sale, the chief financial officer now owns 43,323 shares of the company’s stock, valued at approximately $2,934,700.02. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,836 shares of company stock valued at $5,563,729. 1.85% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Axonics

A number of hedge funds have recently bought and sold shares of the business. RiverPark Advisors LLC increased its holdings in Axonics by 14.4% in the 4th quarter. RiverPark Advisors LLC now owns 1,185 shares of the company’s stock valued at $74,000 after buying an additional 149 shares during the period. Metropolitan Life Insurance Co NY increased its stake in shares of Axonics by 5.9% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 3,120 shares of the company’s stock valued at $195,000 after acquiring an additional 175 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Axonics by 5.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,052 shares of the company’s stock valued at $205,000 after acquiring an additional 209 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of Axonics by 4.3% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 5,169 shares of the company’s stock valued at $290,000 after acquiring an additional 215 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Axonics by 1.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,809 shares of the company’s stock valued at $1,000,000 after purchasing an additional 217 shares in the last quarter. 99.48% of the stock is owned by institutional investors.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.